Lindus Health has secured a grant from Innovate UK Smart Grant and funding from investors to help speed up clinical research trials using its technology platform and machine learning.
As a result of the cash injection, the company is now starting trials to find innovative treatments for a range of conditions including tinnitus, insomnia, menopause and childhood myopia treatments.
Lindus Health is using its technology platform and machine learning to manage trials from start to finish. The CitrusClinical platform delivers an improved patient experience, data visibility and data quality.
The technology is able to significantly speed up the time it takes to approve treatments and get them to market. According to the company, its trials are completed three times more quickly than the conventional industry standard.
£6.5 funding to accelerate trial progress
Funding of £6m was raised from investors, including Firstminute, Seedcamp and Peter Thiel.
In addition, Lindus Health has also received a grant for almost £500,000 from Innovate UK Smart Grant, part of UK Research and Innovation (UKRI). Assessors from UKRI described its work in machine learning and data science as a “hugely valuable and game-changing project”.
Michael Young, co-founder of Lindus Health, said: “Clinical trials are the biggest bottleneck to improving human health. We’re working with high-growth companies developing the next wave of breakthrough treatments to accelerate the clinical trials process.
“It’s fantastic to be working with the government and industry pioneers to revolutionise clinical trials to deliver treatments to benefit patients more quickly.
“From monitoring trial data in real-time to using machine learning to predict trial outcomes and make improvements to trial designs in advance, we want to simplify and accelerate the trials process and put patients first.”
The company will now use the funding to accelerate its use of machine learning and data science to revolutionise clinical trials. In doing so, it will help improve and extend lives, by bringing treatments to patients more quickly.
The company is set for a number of trials. It is working with Pharmanovia to evaluate the safety and efficacy of a treatment for severe insomnia, using digital technology to find hard-to-reach insomnia patients. It is also running a 200-person trial, evaluating Oto’s digital tinnitus solution against in-person therapy.
Lindus Health is also running trials for Type 2 diabetes with George Medicines, and for the MyopiaX treatment for children affected by progressive short-sightedness with Dopavision.
Last year we saw The NHS Somerset, Wiltshire, Avon and Gloucester (SWAG) Cancer Alliance team up with Inspirata to use AI to speedily match patients with relevant trials.